The School of Medicine, the Duke Comprehensive Cancer Institute, and the Institute for Genome Science & Policy have collaborated to create a Proteomics Core Facility to provide protein characterization resources for Duke Comprehensive Cancer Institute members and the entire Duke Research Gommunity. The Proteomics Core Facility ( is located in a ~1,900 sq. ft. laboratory in the Levine Science Research Center, and provides capabilities for mass spectrometry based proteomics for protein identification and protein quantitation, including biomarker discovery and biomarker verification experiments.'For qualitative identificafions and biomarker discovery experiments ('omic-scale qualitative and quantitative analyses), the laboratory is equipped with four high resolution accurate mass LC/MS/MS systems, each using a dedicated ultra-high performance nanoscale liquid chromatography systems (Waters NanoAcquity). Three ofthe MS/MS systems are hybrid quadruple time-of-fiight tandem mass spectrometers (Waters Q-Tof Ultima, Q-Tof Premier, and Synapt High Definition Mass Spectrometer). The fourth system is a hybrid linear ion trap - orbitrap system (Thermo's LTQ-Orbitrap). These systems can be used for label-free, gel-free'differential expression experiments, and also for isotope coding proteomics (such as SILAC or ITRAQ). For biomarker verification experiments, targeted mass spec quantitative experiments are performed on an ultra-high performance nanoscale LC system coupled to a triple quadrupole tandem mass spectrometer (Waters Quattro Premier). For these experiments, data acquisition is accomplished using LC/MS/MS with Mulfiple Reacfion Monitoring, a technology whiqh is the 'Gold Standard'for clinical pharmacokinetics studies. In addition, the Synapt High Definition: Mass Spectrometer (Q-Tof with an ion-mobility mass analyzer) provides for unique experiments characterizing piepfides and proteins not only on the basis of mass and charge, but also molecular shape/size, using a unique ionmobility cell located between the quadrupole and fime-of-fiight mass analyzers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Adams, Rebecca N; Mosher, Catherine E; Blair, Cindy K et al. (2015) Cancer survivors' uptake and adherence in diet and exercise intervention trials: an integrative data analysis. Cancer 121:77-83
Pruszynski, Marek; Koumarianou, Eftychia; Vaidyanathan, Ganesan et al. (2014) Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. J Nucl Med 55:650-6
Batinic-Haberle, Ines; Tovmasyan, Artak; Roberts, Emily R H et al. (2014) SOD therapeutics: latest insights into their structure-activity relationships and impact on the cellular redox-based signaling pathways. Antioxid Redox Signal 20:2372-415
Sachdeva, Mohit; Mito, Jeffrey K; Lee, Chang-Lung et al. (2014) MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. J Clin Invest 124:4305-19
Tovmasyan, Artak; Carballal, Sebastian; Ghazaryan, Robert et al. (2014) Rational design of superoxide dismutase (SOD) mimics: the evaluation of the therapeutic potential of new cationic Mn porphyrins with linear and cyclic substituents. Inorg Chem 53:11467-83
Azrad, Maria; Demark-Wahnefried, Wendy (2014) The association between adiposity and breast cancer recurrence and survival: A review of the recent literature. Curr Nutr Rep 3:9-15
Blair, Cindy K; Madan-Swain, Avi; Locher, Julie L et al. (2013) Harvest for health gardening intervention feasibility study in cancer survivors. Acta Oncol 52:1110-8
Mito, Jeffrey K; Min, Hooney D; Ma, Yan et al. (2013) Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma. J Pathol 229:132-40
Pruszynski, Marek; Koumarianou, Eftychia; Vaidyanathan, Ganesan et al. (2013) Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. Nucl Med Biol 40:52-9
Hover, Bradley M; Loksztejn, Anna; Ribeiro, Anthony A et al. (2013) Identification of a cyclic nucleotide as a cryptic intermediate in molybdenum cofactor biosynthesis. J Am Chem Soc 135:7019-32

Showing the most recent 10 out of 161 publications